BioMarin Pharmaceutical Inc. (BMRN) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à San Rafael, CA, United States. Le PDG actuel est Alexander Hardy.
BMRN a date d'introduction en bourse 1999-07-26, 3,040 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $10.67B.
BioMarin Pharmaceutical Inc. is a biopharmaceutical company that develops and commercializes therapies for rare and life-threatening genetic and metabolic diseases. The company's approved commercial products include Vimizim and Naglazyme for mucopolysaccharidosis disorders, Kuvan and Palynziq for phenylketonuria, Brineura for Batten disease, Voxzogo for achondroplasia, and Aldurazyme for lysosomal storage disease. BioMarin's pipeline includes late-stage gene therapy candidates such as valoctocogene roxaparvovec for hemophilia A and BMN 307 for phenylketonuria, along with BMN 255 in development for primary hyperoxaluria. The company distributes its products globally through specialty pharmacies, hospitals, and pharmaceutical wholesalers across the United States, Europe, Latin America, and international markets, while maintaining strategic partnerships with leading biotechnology firms.
